Redpoint Bio (RPBC) Stock Price, News & Analysis

Company Overview

Redpoint Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel immunotherapies for cancer and inflammatory diseases. The company’s proprietary Receptor-Ligand Pairing (RLP™) platform enables the design of targeted biologics that selectively activate or inhibit immune cell pathways. By leveraging high-throughput screening and structure-guided engineering, Redpoint Bio aims to deliver next-generation antibodies and fusion proteins with improved efficacy and safety profiles compared to conventional therapies.

Redpoint Bio’s pipeline includes multiple therapeutic candidates in various stages of preclinical and early clinical development. Lead programs target checkpoint pathways in solid tumors, while additional candidates are directed toward cytokine modulation for autoimmune and inflammatory disorders. The company’s strategic approach combines multidisciplinary expertise in molecular biology, bioengineering and translational immunology to advance its product candidates efficiently through proof-of-concept studies and into later-stage trials.

Founded in 2016 and headquartered in Redwood City, California, Redpoint Bio operates research facilities in the San Francisco Bay Area and collaborates with academic institutions and contract research organizations across North America and Europe. The company has secured partnerships for manufacturing and distribution to support future commercialization efforts. Its global footprint and integrated R&D capabilities position Redpoint Bio to address unmet medical needs in diverse patient populations.

Under the leadership of Chief Executive Officer Dr. Anna Chang, a veteran of the biotechnology industry with previous roles at leading immuno-oncology firms, Redpoint Bio is guided by an experienced management team and board of directors. The team’s collective expertise spans drug discovery, clinical development and regulatory affairs, supporting the company’s mission to develop safe and effective treatments that transform patient care in oncology and immunology.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0001
• Volume: 200,000 shs
• Average Volume: 101,150 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RPBC Stock Analysis - Frequently Asked Questions

How have RPBC shares performed this year?

Redpoint Bio's stock was trading at $0.0001 at the beginning of 2025. Since then, RPBC stock has increased by 0.0% and is now trading at $0.0001.

How do I buy shares of Redpoint Bio?

Shares of RPBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Redpoint Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Redpoint Bio investors own include Twitter (TWTR), Towne Bank (TOWN), Hershey (HSY), Ferro (FOE) and BMC Stock (BMCH).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Commercial Physical Research
• Sub-Industry: Business Services
• Current Symbol: OTCMKTS:RPBC
• CIK: 1328003
• Web: www.redpointbio.com
• Phone: 215-456-2312
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A